行情

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

实时行情|Nasdaq Last Sale

0.8325
-0.0775
-8.52%
盘后: 0.7990 -0.0335 -4.02% 19:39 01/24 EST
开盘
0.8872
昨收
0.9100
最高
0.8900
最低
0.8000
成交量
153.92万
成交额
--
52周最高
4.320
52周最低
0.4030
市值
213.88万
市盈率(TTM)
-1.2487
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INNT 新闻

  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前
  • 瑞幸咖啡捐赠1000万元 助力疫情防控
  • 新浪科技.3小时前
  • 法国撤侨方案:大巴先送至长沙隔离14日
  • 观察者网.4小时前
  • 贝索斯手机遭入侵 手机窃听再次成为焦点
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

INNT 简况

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
展开

Webull提供Innovate Biopharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。